Increased frequency of clindamycin-resistant Cutibacterium acnes strains isolated from Japanese patients with acne vulgaris caused by the prevalence of exogenous resistance genes
- PMID: 36880295
- DOI: 10.1111/1346-8138.16757
Increased frequency of clindamycin-resistant Cutibacterium acnes strains isolated from Japanese patients with acne vulgaris caused by the prevalence of exogenous resistance genes
Abstract
Cutibacterium acnes, a resident bacterium of the skin, is a target for antimicrobial treatment of acne vulgaris, because it exacerbates inflammation. Recently, antimicrobial-resistant C. acnes strains have been isolated worldwide, and their prevalence has led to failure of antimicrobial treatment. This study aimed to analyze the antimicrobial resistance of C. acnes strains isolated from Japanese patients with acne vulgaris who visited the hospital and dermatological clinics between 2019 and 2020. Resistance rates to roxithromycin and clindamycin increased during 2019 to 2020 compared with those during 2013 to 2018. Additionally, the proportion of doxycycline-resistant and low-susceptibility strains (minimum inhibitory concentration [MIC] ≥8 μg/mL) increased. No difference in clindamycin resistance rates between patients with and without a history of antimicrobial use was observed during 2019 to 2020, which were significantly higher for patients with a history than for patients without a history during 2016 to 2018. The proportion of high-level clindamycin-resistant strains (MIC ≥256 μg/mL) gradually increased; particularly, the resistance rate was 2.5 times higher in 2020 than that in 2013. The proportion of strains showing high-level clindamycin resistance that also have the exogenous resistance genes erm(X) or erm(50), which confer high resistance, showed a strong positive correlation (r = 0.82). Strains with the multidrug resistance plasmid pTZC1 encoding erm(50) and tet(W) genes were frequent in clinic patients. Notably, most strains with erm(X) or erm(50) were classified as single-locus sequence types A and F (traditional types IA1 and IA2). Our data show that the prevalence of antimicrobial-resistant C. acnes is increasing in patients with acne vulgaris attributable to acquisition of exogenous genes in specific strains. To control the increasing prevalence of antimicrobial-resistant strains, it is important to select the appropriate antimicrobials while taking into consideration the latest information on resistant strains.
Keywords: Cutibacterium acnes; acne vulgaris; clindamycin resistance; erm(X); pTZC1.
© 2023 Japanese Dermatological Association.
Similar articles
-
Characterization of acne patients carrying clindamycin-resistant Cutibacterium acnes: A Japanese multicenter study.J Dermatol. 2020 Aug;47(8):863-869. doi: 10.1111/1346-8138.15397. Epub 2020 May 18. J Dermatol. 2020. PMID: 32424832
-
Transconjugation of erm(X) conferring high-level resistance of clindamycin for Cutibacterium acnes.J Med Microbiol. 2019 Jan;68(1):26-30. doi: 10.1099/jmm.0.000875. Epub 2018 Nov 15. J Med Microbiol. 2019. PMID: 30431414
-
Increased prevalence of doxycycline low-susceptible Cutibacterium acnes isolated from acne patients in Japan caused by antimicrobial use and diversification of tetracycline resistance factors.J Dermatol. 2021 Sep;48(9):1365-1371. doi: 10.1111/1346-8138.15940. Epub 2021 May 17. J Dermatol. 2021. PMID: 33998707
-
Prevalence of antibiotic-resistant Cutibacterium acnes (formerly Propionibacterium acnes) isolates, a systematic review and meta-analysis.J Glob Antimicrob Resist. 2024 Dec;39:82-91. doi: 10.1016/j.jgar.2024.07.005. Epub 2024 Aug 22. J Glob Antimicrob Resist. 2024. PMID: 39179105
-
Antibiotics and Antimicrobial Resistance in Acne: Epidemiological Trends and Clinical Practice Considerations.Yale J Biol Med. 2022 Dec 22;95(4):429-443. eCollection 2022 Dec. Yale J Biol Med. 2022. PMID: 36568833 Free PMC article. Review.
Cited by
-
Antibiotic resistance rates in Cutibacterium acnes isolated from patients with acne vulgaris: a systematic review and meta-analysis.Front Microbiol. 2025 Jun 4;16:1565111. doi: 10.3389/fmicb.2025.1565111. eCollection 2025. Front Microbiol. 2025. PMID: 40535003 Free PMC article.
-
Effectiveness and Safety of a Dermocosmetic Cream as an Adjunct to Adapalene for Mild and Moderate Acne in Indonesia: Results of a Multicenter Randomized Controlled Study.Clin Cosmet Investig Dermatol. 2024 Oct 15;17:2283-2296. doi: 10.2147/CCID.S474331. eCollection 2024. Clin Cosmet Investig Dermatol. 2024. PMID: 39430644 Free PMC article.
-
Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology.J Clin Aesthet Dermatol. 2024 Aug;17(8):29-40. J Clin Aesthet Dermatol. 2024. PMID: 39148960 Free PMC article. Review.
-
Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease.Antibiotics (Basel). 2024 Mar 17;13(3):270. doi: 10.3390/antibiotics13030270. Antibiotics (Basel). 2024. PMID: 38534705 Free PMC article. Review.
References
REFERENCES
-
- Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nat Rev Microbiol. 2018;16:143-55.
-
- Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence? Br J Dermatol. 2008;158:442-55.
-
- Xu H, Li H. Acne, the skin microbiome, and antibiotic treatment. Am J Clin Dermatol. 2019;20:335-44.
-
- Hayashi N, Akamatsu H, Iwatsuki K, Shimada-Omori R, Kaminaka C, Kurokawa I, et al. Japanese dermatological association guidelines: guidelines for the treatment of acne vulgaris 2017. J Dermatol. 2018;45:898-935.
-
- Nakase K, Aoki S, Sei S, Fukumoto S, Horiuchi Y, Yasuda T, et al. Characterization of acne patients carrying clindamycin-resistant Cutibacterium acnes: a Japanese multicenter study. J Dermatol. 2020;47:863-9.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical